Direct compression of liraglutide acetate for low-dose tablets begins with a particle-size mismatch between the cohesive peptide acetate and common direct-compression diluents such as anhydrous dibasic calcium phosphate, mannitol, and silicified microcrystalline cellulose. The acetate salt, when released from cold storage at 2–8 °C and exposed to ambient relative humidity above 60 % RH, forms electrostatic agglomerates and localized peptide-rich domains that persist through low-shear bin blending. A staged preblend is therefore prepared at a 1:10 (w/w) peptide-to-diluent ratio, screened through a 500 µm mesh, and then added to a diffusion mixer. Content uniformity testing per USP <905> uses an acceptance value ≤ 15.0 for low-dose tablets; blend uniformity RSD above 5.0 % at 10 kg scale is a common rejection threshold during process validation. The tablet press is a rotary machine with external lubrication to minimize magnesium stearate, which is limited to 0.25–1.0 % w/w because the lipophilic peptide surface binds magnesium stearate and delays tablet disintegration under USP <701>. The terminal tablet is film-coated with a low-moisture aqueous coating system; organic coating solvents are avoided to prevent peptide aggregation. Residual moisture by Karl Fischer titration USP <921> Method Ia is controlled below 2.0 % w/w. Published dissolution data for an approved oral liraglutide tablet are limited; therefore USP <711> apparatus 2 with a surfactant-containing medium at 37 °C is used to reduce peptide adsorption to glass and vessel surfaces. The release specification includes assay by HPLC-UV per Ph. Eur. 2.2.29, related peptides, dissolution, uniformity of dosage units, water content, and microbial limits per USP <61> and USP <62>.

Why Does Aqueous Liraglutide Acetate Demand pH 8.15 Rather Than the Native GLP-1 pH 7.4?

The acetate salt of liraglutide releases acetic acid upon dissolution, creating an acidic microenvironment that promotes peptide aggregation and subcutaneous irritation. Liraglutide is a glucagon-like peptide 1 (7-37) analogue with Lys34Arg substitution and N-ε-(γ-Glu(N-α-hexadecanoyl)) acylation at Lys26; the acetate counterion must be corrected in assay calculations to express strength as liraglutide free base equivalent. The marketed 6 mg/mL prefilled pen solution is adjusted to pH 8.15 with sodium hydroxide and hydrochloric acid, measured potentiometrically per USP <791> and Ph. Eur. 2.2.3. At this pH the glutamic acid spacer and the C16 hexadecanoyl side chain maintain sufficient electrostatic repulsion to suppress hydrophobic aggregation of the peptide monomer. Aqueous formulation must be prepared in a closed jacketed vessel at 10–20 °C under nitrogen sparge to reduce methionine oxidation; antioxidant addition is avoided because thiol-based agents can cleave the acylation bond. Sterile filtration employs a 0.22 µm low-protein-binding PVDF membrane, because untreated PES and nylon membranes adsorb liraglutide monomer at concentrations above 2 mg/mL and reduce assay recovery. The formulated liquid is filled into 3 mL glass cartridges under EU GMP Annex 1 Grade A conditions within an ISO 14644-1 Class 5 environment; filling pump speed is validated to avoid cavitation and peptide shear-induced aggregation. Terminal product testing includes USP <788> particulate matter limits of ≤ 6000 particles ≥ 10 µm and ≤ 600 particles ≥ 25 µm per container for small-volume parenterals, bacterial endotoxins per USP <85>, sterility per USP <71>, and container closure integrity per USP <1207>. The preservative phenol is used in multidose cartridges; its concentration is verified by HPLC per Ph. Eur. 2.2.29 because peptide-phenol adducts can form at elevated storage temperature above 25 °C.

Low-dose oral capsule and granule operations for liraglutide acetate avoid aqueous granulation because water accelerates deamidation and hydrolysis at the peptide backbone. Instead, a hydroalcoholic binder system containing ethanol or isopropyl alcohol is used in a high-shear granulator fitted with an end-point power monitor. The API is added at 0.5–2.0 % w/w to the dry mixture of microcrystalline cellulose and anhydrous lactose; granulation is completed at bed temperature below 30 °C and then dried in a fluid-bed dryer to residual moisture below 2.0 % w/w. Residual solvent levels are quantified by headspace GC per USP <467> and must comply with ICH Q3C Class 3 limits, which permit 5000 ppm for ethanol and isopropyl alcohol. Granule fraction analysis by sieving shows that the peptide concentrates in the fines below 75 µm, so a regranulation step or external granule spraying is required to equalize distribution. The dried granules are filled into hard gelatin or HPMC capsules using a dosator or tamping pin filling machine; weight variation is controlled per USP <905> while disintegration is evaluated per USP <701>. The terminal capsule product is intended for oral peptide delivery with an enteric coating applied to the filled capsule or to multiparticulate pellets before filling. Published data for this specific configuration is limited; therefore a biphasic dissolution test per USP <711> with pH 1.2 acid stage followed by pH 6.8 buffer is used to discriminate batch failure caused by premature coat rupture.

When Delayed-Release Oral Delivery Is Required, Multiparticulate Coating Replaces Single-Tablet Coatings

Delayed-release oral delivery of liraglutide acetate is not an approved commercial route, but development batches use multiparticulate systems because a single-tablet enteric coat fails mechanically on peptide-lipid cores. Sugar spheres of 300–500 µm are layered with liraglutide acetate and a low-viscosity binder in a fluid-bed coater; the layering suspension is prepared at 1:10 peptide-to-binder ratio to prevent nozzle blockage. The layered pellets are coated with a methacrylic acid–ethyl acrylate copolymer dispersion, targeted for dissolution at pH 5.5 or above. A seal coat of HPMC is applied between the drug layer and enteric coat to prevent peptide-enteric polymer interaction; without the seal coat, free carboxyl groups on methacrylic acid copolymer ion-pair with basic amino acid side chains and slow release irreproducibly. Coating weight gain is controlled at 8–12 % w/w for the seal coat and 10–20 % w/w for the enteric coat; the final pellets are filled into HPMC capsules. The terminal dosage form is tested for acid resistance in 0.1 M hydrochloric acid for 2 h, followed by dissolution at pH 6.8 per USP <711>. Published data for oral liraglutide multiparticulate bioavailability is limited; the formulation is intended to protect the peptide from gastric pepsin and to release it in the upper small intestine for subsequent absorption enhancement. Residual moisture after coating must be below 2.0 % w/w to prevent polymer film peel-off and peptide hydrolysis.

Lyophilized Liraglutide Acetate Reservoir Powders Require a Collapse-Temperature-Driven Cycle

For lyophilized injectable presentations, liraglutide acetate is formulated as a bulk reservoir powder that must remain below its collapse temperature during primary drying. The acetate counterion shifts the glass transition of the freeze-concentrated solute, so a standard peptide lyophilization cycle with a primary drying shelf temperature of −20 °C may collapse if the product temperature exceeds the collapse temperature. Formulation typically includes a disaccharide stabilizer such as sucrose or trehalose at 3–5 % w/v, and an acetate buffer system prepared from the peptide counterion is used to reduce pH shift during freezing. The lyophilization cycle is developed using differential scanning calorimetry and freeze-drying microscopy to identify the collapse temperature; published data for liraglutide acetate in this specific configuration is limited, so the collapse value is measured for each batch lot rather than assumed. Primary drying is performed at a chamber pressure of 50–100 mTorr, with shelf temperature ramping at 0.5 °C/min; secondary drying at 25–35 °C reduces residual moisture to below 1.0 % w/w by USP <921> Method Ic. The terminal lyophilized cake is reconstituted with water for injection to a target liraglutide concentration of 6 mg/mL, and the reconstituted solution must be clear with no visible particles under USP <790>. Sterility is achieved by sterile filtration before lyophilization; the finished vials are tested per USP <71> for sterility and USP <85> for endotoxin.

Stability-Indicating HPLC Resolution Conditions for Liraglutide Acetate and Related Peptides

Release and stability testing for liraglutide acetate API in solid and liquid dosage forms requires a stability-indicating HPLC-UV method capable of resolving the parent peptide from deamidated, oxidized, and acylated-related impurities. A C18 column with 150 mm length, 4.6 mm internal diameter, and 3.5 µm particle size is operated at 30 °C with a mobile phase of phosphate buffer pH 7.4 and an acetonitrile gradient from 30 % to 50 % acetonitrile over 40 min. Detection is at 214 nm for peptide bonds; the acetate peak elutes near the void and is quantified by ion chromatography per Ph. Eur. 2.2.29 if residual acetate content requires control. Forced degradation studies are run according to ICH Q1A(R2): acid hydrolysis in 0.1 M HCl at 40 °C for 24 h, base hydrolysis in 0.1 M NaOH at 25 °C for 24 h, oxidation in 0.3 % hydrogen peroxide at 25 °C for 6 h, and thermal stress at 60 °C for 14 days. The method must show resolution ≥ 2.0 between liraglutide and the nearest eluting related peptide; tailing factor for the parent peak is set between 0.8 and 1.5 per USP <621>. System suitability includes relative standard deviation of peak area ≤ 2.0 % from five injections and limit of quantitation ≤ 0.1 % w/w. The method is used for tablet, capsule, granule, and prefilled pen stability batches; it is transferred to QC laboratories under ICH Q2(R1) validation protocols. The terminal output is a certificate of analysis that reports liraglutide free base equivalent, related peptides, water content, residual solvents, microbial quality, and elemental impurities under ICH Q3D.